The Competition Tribunal dismissed a lawsuit by Laboratorios Recalcine S.A. against Laboratorio Novartis Chile S.A.. The Tribunal considered that there was reasonable doubt regarding the real composition of the product ZEITE, doubt that justified Novartis’s judicial and administrative actions, the latter being the owner of an invention patent over the active ingredient Imatinib Mesilato in its Beta crystallization. Regarding the legal actions that were started after it was determined that the substance used by Novartis was not the protected active ingredient, the Tribunal considered that they are not a possible infraction by Recalcine with regard to Novartis’s industrial property rights, but an improper use of non disclosed scientific information.
